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(OR = 1.18; 1.13–1.22), high chronic disease scores (CDS
10+: OR = 1.15; 1.10–1.20; CDS 5–9: OR = 1.13
(1.09–1.17). Previous use of gastroprotective agents,
indicative of a history of gastropathy, was negatively
associated with persistency: (OR = 0.92; 0.88–0.95). Age,
gender, dosage at initiation, prescriber’s specialty, and
income level did not inﬂuence persistency. CONCLU-
SION: Persistency beyond three months was higher for
coxibs than for non-selective NSAIDs.
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OBJECTIVES: There is a long-standing debate over the
theory that innovations (including innovative pharma-
ceuticals) are largely funded internally by companies.
Supporters of this theory assert that R&D is ﬁnanced
internally from sales, while opponents argue, that R&D
investment is unrelated to sales. The objective of this
study is to empirically test the internal funding theory for
pharmaceutical R&D and suggest policy implications
based on the results. METHODS: Data for US pharma-
ceutical sales, R&D expenditure, proﬁtability (both series
are for 1980 to 2001), and new chemical entity (NCE)
sales (all NCEs approved from 1988 to 2001) are used in
least squares time series regressions to explain variation
in annual percent change in R&D expenditure. Log-log
regressions are used to model the relationship of the
dependent variable to percent change in annual US phar-
maceutical sales and NCE 3-year future sales. A full
model also is estimated. Linear-log models of percentage
change in pharmaceutical sales are estimated for percent
return on stockholders’ equity, percent 10-year return,
and percent annual return. Series were tested for trends,
and, where appropriate, sensitivity analyses were con-
ducted on models. RESULTS: Empirical evidence from
the analyses support the hypothesis that pharmaceutical
R&D is internally funded from sales. The sales coefﬁcient
was estimated to be 1.2% (p < 0.001) and the coefﬁcient
for NCEs 3-year future sales was 0.4% (p < 0.001). When
a full model is estimated with these variables, the coefﬁ-
cients were virtually unchanged and remained statistically
signiﬁcant. Coefﬁcients for the proﬁtability model were
0.09 for percent return on stockholders’ equity, 0.05 for
10-year return, and 0.04 for annual return. CONCLU-
SIONS: The importance of sales for funding pharmaceu-
tical R&D is demonstrated. Policies detrimental to this
relationship should be expected to cause a shift of R&D
effort from the US or to reduce R&D investment in
general.
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OBJECTIVE: Brand loyalty is an elusive, but sought after
consumer attribute. Loyalty, however, is not clearly
deﬁned; especially for pharmaceuticals that have only
recently been associated with their brands. METHODS:
Brand loyalty was assessed from a national Health care
survey, ﬁelded June 2002 to 30,000 online U.S. adults.
For this analysis, three conditions were chosen to repre-
sent a range of consumer types. Respondents (n = 7,209)
were diagnosed and taking a prescription (Rx) for: de-
pression (20% diagnosed, 51% Rx), gastroesophageal
reﬂux disease (GERD, 10% diagnosed, 64% Rx), and/or
high cholesterol (23% diagnosed, 53% Rx). Loyalty was
evaluated by summing four Health care attitudes: would
ask doctor for prescription; prescription advertising pro-
vides useful information; would ask doctor for speciﬁc
medication; and insist that doctor give brand name med-
ication. Responses were on a 5-point scale: 1 = strongly
disagree and 5 = strongly agree. Final scores ranged from
4–20 (mean = 12, standard deviation = 2.8). Loyalty was
then categorized as low (score 4–9) 18%, moderate
(10–14) 65%, and high (15–20) 16%. RESULTS: Loyal
consumers were younger, with more severe disease and
comorbid illnesses. They sought information frequently
and from more sources. Notably, loyal consumers re-
quested medications more than three times more than
those with low loyalty. Between 9–19% requested one of
their high cholesterol, depression, or GERD medications.
Requesters were more likely to be men. They had posi-
tive, proactive Health care attitudes and sought infor-
mation from a variety of sources. Notably, consumers
who requested medications remained on them up to six
months longer. CONCLUSIONS: There is a small, but
distinct group of pharmaceutical brand loyalists that is
proactive and more likely to request prescription med-
ications. Those who request medications trust doctors’
advice and stay on therapy longer. These are our target
patients. They can be reached through doctors, the inter-
net, and family and friends with the information they
need to make sound Health care decisions.
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OBJECTIVES: To demonstrate the use of bayesian 
decision theory to establish optimal commercial drug
development programmes. METHODS: A probabilistic
model of a drug in development was used to estimate 
the expected net return of alternative development pro-
